Tuberous sclerosis complex (TSC) is a rare autosomal dominant genetic syndrome with an approximate incidence of 1 in 5000–10,000 live births.1,2 TSC patients have a mutation in the TSC1 or TSC2 genes, which encode for hamartin and tuberin, respectively.1,3 These inactivating mutations result in the deregulation of the mammalian target to rapamycin (mTOR) pathway. Here, MTOR is linked to tuberous sclerosis.